Abstract

Recently, the interest in plant-derived antimicrobial agents has increased. However, there are no sufficient studies dealing with their modes of action. Herein, we investigate an in-house library of common plant-based phenolic compounds for their potential antibacterial effects against the methicillin-resistant Staphylococcus aureus (MRSA), a widespread life-threatening superbug. Flavonoids, which are considered major constituents in the plant kingdom, were found to be a promising class of compounds against MRSA, particularly the non-glycosylated ones. On the other hand, the glycosylated derivatives, along with the flavonolignan silibinin A, were able to restore the inhibitory activity of ampicillin against MRSA. To explore the mode of action of this class, they were subjected to an extensive inverse virtual screening (IVS), which suggested penicillin-binding protein 2a (PBP2a) as a possible target that mediates both the antibacterial and the antibiotic-synergistic effects of this class of compounds. Further molecular docking and molecular dynamic simulation experiments were conducted to support the primary IVS and the in vitro results and to study their binding modes with PBP2a. Our findings shed a light on plant-derived natural products, notably flavonoids, as a promising and readily available source for future adjuvant antimicrobial therapy against resistant strains.

Highlights

  • In 2018, the World Health Organization (WHO) announced that the number of antibiotic-resistant pathogenic bacteria had alarmingly increased to reach a perilous level that required a global cooperation [1]

  • We decided to utilize some of these approaches to suggest suitable methicillin-resistant Staphylococcus aureus (MRSA) targets for our

  • The result of this study indicated that hesperetin (6), apigenin (4), and chrysin (5) have an additive effect with the β-lactam antibiotic ampicillin (FICI = 1)

Read more

Summary

Introduction

In 2018, the World Health Organization (WHO) announced that the number of antibiotic-resistant pathogenic bacteria had alarmingly increased to reach a perilous level that required a global cooperation [1]. About 2.8 million people are infected with antibiotic-resistant bacteria annually in the United States, with more than 35,000 dying as a result [2]. These superbugs are spreading globally, and the continuous emergence of new resistance mechanisms make our ability to treat common infectious diseases and some nosocomial infections a real challenge. The rate of new antibiotic development does not match the rate of growing resistance. Besides improving the general awareness of proper antibiotics use, finding novel antibiotics should be a priority for a lot of research groups working in the field of drug discovery

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call